Compare CSGP & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSGP | UTHR |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 23.9B |
| IPO Year | 1998 | 1999 |
| Metric | CSGP | UTHR |
|---|---|---|
| Price | $42.75 | $528.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | $74.77 | ★ $531.79 |
| AVG Volume (30 Days) | ★ 5.2M | 497.9K |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | 0.02 | ★ 27.86 |
| Revenue | $965,230,000.00 | ★ $1,483,300,000.00 |
| Revenue This Year | $19.71 | $7.05 |
| Revenue Next Year | $12.40 | $13.30 |
| P/E Ratio | $2,141.50 | ★ $18.93 |
| Revenue Growth | ★ 15.23 | 2.38 |
| 52 Week Low | $41.84 | $266.98 |
| 52 Week High | $97.43 | $548.12 |
| Indicator | CSGP | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 57.52 |
| Support Level | N/A | $464.92 |
| Resistance Level | $49.03 | $542.66 |
| Average True Range (ATR) | 1.58 | 14.24 |
| MACD | 0.12 | 1.62 |
| Stochastic Oscillator | 13.10 | 74.46 |
CoStar Group is a leading provider of commercial real estate data and marketplace listing platforms. Its data offering contains in-depth analytical information on over 5 million commercial real estate properties related to various subsectors spanning office, retail, hotels, multifamily, healthcare, industrial, self-storage, and data centers. It operates many well-respected brands such as CoStar Suite, LoopNet, Apartments.com, BizBuySell, and Lands of America, with more than 80% of its revenue classified as subscription-based. The company recently expanded its presence into Canada, the United Kingdom, Spain, and France.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.